GH Guardant Health, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
15:26
Aug 19
Aug 19
Author credits a basket with saving them from semi weakness.
Author credits a basket with saving them from semi weakness, explicitly holds positions from the screenshot, and calls MRNA's case a clear catalyst for AI in drug discovery while earlier listing TWST, TEM, and GH as favorites.
14:05
Aug 10
Aug 10
GH on AI drug discovery watchlist
Author names GH as a favorite watchlist pick tied to expected OAI Astra model release and recent earnings showing AI accelerating drug discovery; no confirmed position disclosed.
MED
06:32
Aug 10
Aug 10
GH on AI drug discovery watchlist
Author names GH as a weekend watchlist favorite tied to anticipated OAI Astra release and recent earnings highlighting AI-driven drug discovery acceleration.
MED
13:06
Aug 04
Aug 04
A news wire reports a broad list of price target increases from multiple analysts across dozens.
A news wire reports a broad list of price target increases from multiple analysts across dozens of stocks, with no directional commentary from the account itself.
11:40
Jul 31
Jul 31
A news wire reports a broad wave of price target increases across multiple stocks from various.
A news wire reports a broad wave of price target increases across multiple stocks from various analysts, with no explicit directional calls made by the account itself.
08:30
Jul 23
Jul 23
Quest serves as a collection and testing partner for Guardant's Shield colon cancer screening test, but management declined to disclose volumes.
HIGH
08:30
Jul 19
Jul 19
Buy Guardant Health and Natera on biotech rotation.
Retail investors are rotating out of crowded tech positions into biotech and healthcare. Guardant Health (liquid biopsy, early cancer detection) and Natera (genetic testing, recurrence monitoring) are leading liquid-biopsy companies that rank high among retail purchases. This rotation into defensive biotech leaders gives them added demand and supports a positive outlook.
MED
12:24
May 13
May 13
Long GH as part of a diversified basket of stocks the author buys daily for retirement.
HIGH
12:00
Apr 21
Apr 21
Cancer screening companies are growing rapidly.
Companies like Exact Sciences and Guardant Health are advancing colorectal cancer screening with stool-based and blood tests, respectively, making screening more convenient and increasing adoption. Blood tests are inflecting and multi-cancer early detection tests are emerging, which could lead to earlier cancer detection and better outcomes.
HIGH
08:30
Apr 21
Apr 21
Quest will collect blood samples for Guardant's colon cancer test and list it on their menu; early adoption is underway but volumes are not yet material.
HIGH
08:30
Feb 10
Feb 10
Quest will provide draw services for Guardant's colon cancer blood test, potentially expanding Quest's consumer and oncology volume.
HIGH
08:30
Oct 21
Oct 21
Quest is distributing Guardant's colorectal cancer screening test, expanding Guardant's reach into primary care.
HIGH
About GH Analyst Coverage
Buzzberg tracks GH (Guardant Health, Inc.) across 6 sources. 2 bullish vs 0 bearish calls from 6 analysts. Sentiment: predominantly bullish (17%). 12 total trade ideas tracked. Latest voices: Labubu Trader, DeItaone, Jim Davis.